These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 27342497)

  • 1. [Expression of MCP-1 and CCR2 in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Clinical Significance].
    Wang M; Zhang PP; Zhu Q; Hu ZL; Bai X; Wu YP; Li JJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):112-119. PubMed ID: 38387908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
    Nicolaides C; Fountzilas G; Zoumbos N; Skarlos D; Kosmidis P; Pectasides D; Karabelis A; Giannakakis T; Symeonidis A; Papadopoulos A; Antoniou F; Pavlidis N
    Oncology; 1998; 55(5):405-15. PubMed ID: 9732217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and Clinical Significance of Exosome Component 4 in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma].
    Hong JQ; Huang QH; Huang ZY; Fan LP; Lin QY; Huang HB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1684-1689. PubMed ID: 38071046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study.
    Huang X; Wang Y; Huang Z; Chen X; Lin Q; Huang H; Fan L
    BMC Cancer; 2024 Jan; 24(1):62. PubMed ID: 38212711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL.
    Rungwittayatiwat S; Boonsakan P; Chantrathammachart P; Puavilai T; Pukiat S; Phusanti S; Boonyawat K; Wacharapornin P; Angchaisuksiri P; Ungkanont A; Chuncharunee S; Niparuck P
    Mediterr J Hematol Infect Dis; 2021; 13(1):e2021063. PubMed ID: 34804437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma.
    Xiong W; Li L; Hui X; Liu Y; Li H; Zhang Y; Zhao S
    Clin Transl Oncol; 2024 Sep; 26(9):2240-2249. PubMed ID: 38554189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Features and Prognosis of Patients with CD5
    Huang XJ; Yang J; Wei XF; Fu Y; Zhao YY; Cheng MX; Li QF; Yan HL; Feng YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):750-755. PubMed ID: 38926962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma.
    Liu Y; Zhang H; Zhao S; Zhang Y
    Clin Transl Oncol; 2024 May; ():. PubMed ID: 38773060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma.
    Chen C; Liu S; Jiang X; Huang L; Chen F; Wei X; Guo H; Shao Y; Li Y; Li W
    Exp Hematol Oncol; 2021 Mar; 10(1):20. PubMed ID: 33722306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between Immunohistochemical Subtype and Clinicopathological Features in Patients with Diffuse Large B-cell Lymphoma.
    Patrascu AM; Streba L; Patrascu Ş; Nacea J; Mogoanta L; Rotaru I
    Curr Health Sci J; 2017; 43(3):253-257. PubMed ID: 30595885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aligning outcomes: DLBCL prognosis at a 4th Level University Hospital in Bogotá is comparable to high-income nations, identification of additional prognostic markers for overall survival and relapse.
    Clavijo ND; Aguirre JCF; Del Pilar Agudelo Lopez C; Borda AA; Wills B; Vega GEQ
    Ecancermedicalscience; 2024; 18():1717. PubMed ID: 39021535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of CD30 in Patients with Diffuse Large B-Cell Lymphoma and Clinical Significance].
    Qu Y; Lu XZ; Wang RX; Hei XF; Li J; Xiao BT; Jia ZX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):450-457. PubMed ID: 38660851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].
    Wang KL; Chen C; Shi PF; Yu JH; Tan JF; Qian SX; Gao DQ; Chen K; Liu LR; Xie YP; Xu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1079-1085. PubMed ID: 30111411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and clinical significance of Ki-67 in diffuse large B cell lymphoma].
    Zhou Y; Zhao Y; Bo J; Li YF; Ma C; Shi YN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1162-6. PubMed ID: 24156426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of the correlation between IPI and prognosis in primary breast lymphoma.
    Feng K; Zhao S; Shang Q; Liu J; Yang C; Ren F; Wang X; Wang X
    Am J Cancer Res; 2023; 13(1):245-260. PubMed ID: 36777506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis.
    Xu ML; Gabali A; Hsi ED; Fedoriw Y; Vij K; Salama ME; Ramchandren R; O'Malley D; Wick MR; Battistella M; Gru AA
    Am J Surg Pathol; 2020 Feb; 44(2):e1-e14. PubMed ID: 31567279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of CD30 in Diffuse Large B Cell Lymphoma and Its Clinical Significance].
    Zhao YF; Qian SX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):717-21. PubMed ID: 27342497
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.